Tag Memorial Sloan Kettering Cancer Center

Clinical Trials, News

MSK researchers show an experimental approach to treating pancreatic cancer with the mRNA-based therapeutic cancer vaccine candidate

New data presented by Memorial Sloan Kettering Cancer Center (MSK) researchers show an experimental approach to treating pancreatic cancer with the messenger RNA (mRNA)-based therapeutic cancer vaccine candidate, autogene cevumeran, continues to show potential to stimulate an immune response that…

April 10, 2024

New Treatments, News

FDA approved Truqap in combination with Faslodex for the treatment of adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.

AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or…

November 17, 2023

Clinical Trials, Company News, News

Amgen launches Partners of Choice Network of eight leading oncology academic centers.

THOUSAND OAKS, Calif., Sept. 20, 2023 – Amgen today announced the launch of Amgen Partners of Choice, a new network that brings together Amgen’s oncology research and development experts and world-class clinical leaders at eight research centers across the globe.…

September 20, 2023